Literature DB >> 16843459

The pituitary mediates the anxiolytic-like effects of the vasopressin V1B receptor antagonist, SSR149415, in a social interaction test in rats.

Toshiharu Shimazaki1, Michihiko Iijima, Shigeyuki Chaki.   

Abstract

A vasopressin V(1B) receptor antagonist has been shown to exhibit anxiolytic effects in a variety of animal models of anxiety. In the present study, we examined the involvement of the pituitary in the anxiolytic effects of a vasopressin V(1B) receptor antagonist by conducting a social interaction test in rats. In the sham-operated rats, both the vasopressin V(1B) receptor antagonist SSR149415 and the benzodiazepine chlordiazepoxide significantly increased the social behavior of a pair of unfamiliar rats, and the blood adrenocorticotropic hormone levels were markedly increased during the social interaction test. Hypophysectomy also increased the length of time that the animals engaged in social behavior to the same extent as that observed after treatment of the sham-operated rats with anxiolytics. However, while chlordiazepoxide further increased the duration of social interaction in the hypophysectomized rats, the anxiolytic effects of SSR149415 was no longer observed in these animals. These results suggest that the anxiolytic effects of the vasopressin V(1B) receptor antagonist in the social interaction test are mediated through blockade of the vasopressin V(1B) receptor in the pituitary.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16843459     DOI: 10.1016/j.ejphar.2006.06.032

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

Review 1.  Vasopressin and alcohol: a multifaceted relationship.

Authors:  Kathryn M Harper; Darin J Knapp; Hugh E Criswell; George R Breese
Journal:  Psychopharmacology (Berl)       Date:  2018-11-03       Impact factor: 4.530

2.  Interaction of stress, corticotropin-releasing factor, arginine vasopressin and behaviour.

Authors:  Eléonore Beurel; Charles B Nemeroff
Journal:  Curr Top Behav Neurosci       Date:  2014

3.  Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325.

Authors:  M Iijima; T Yoshimizu; T Shimazaki; K Tokugawa; K Fukumoto; S Kurosu; T Kuwada; Y Sekiguchi; S Chaki
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

4.  Role of the vasopressin 1b receptor in rodent aggressive behavior and synaptic plasticity in hippocampal area CA2.

Authors:  J H Pagani; M Zhao; Z Cui; S K Williams Avram; D A Caruana; S M Dudek; W S Young
Journal:  Mol Psychiatry       Date:  2014-05-27       Impact factor: 15.992

Review 5.  The vasopressin 1b receptor and the neural regulation of social behavior.

Authors:  Erica L Stevenson; Heather K Caldwell
Journal:  Horm Behav       Date:  2011-12-07       Impact factor: 3.587

Review 6.  From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use?

Authors:  I S McGregor; P D Callaghan; G E Hunt
Journal:  Br J Pharmacol       Date:  2008-05       Impact factor: 8.739

Review 7.  Innovative approaches for the treatment of depression: targeting the HPA axis.

Authors:  Fiona Thomson; Mark Craighead
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

8.  Asymmetric catalytic aza-Morita-Baylis-Hillman reaction for the synthesis of 3-substituted-3-aminooxindoles with chiral quaternary carbon centers.

Authors:  Fang-Le Hu; Yin Wei; Min Shi; Suresh Pindi; Guigen Li
Journal:  Org Biomol Chem       Date:  2013-02-13       Impact factor: 3.876

Review 9.  Vasopressin: behavioral roles of an "original" neuropeptide.

Authors:  Heather K Caldwell; Heon-Jin Lee; Abbe H Macbeth; W Scott Young
Journal:  Prog Neurobiol       Date:  2007-11-04       Impact factor: 11.685

10.  The nonpeptide oxytocin receptor agonist WAY 267,464: receptor-binding profile, prosocial effects and distribution of c-Fos expression in adolescent rats.

Authors:  C Hicks; W Jorgensen; C Brown; J Fardell; J Koehbach; C W Gruber; M Kassiou; G E Hunt; I S McGregor
Journal:  J Neuroendocrinol       Date:  2012-07       Impact factor: 3.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.